Bruna Angelelli
- Hepatology top 5%
- Hepatocellular Carcinoma Treatment and Prognosis 5
- Oncology top 10%
- Cancer Treatment and Pharmacology 9
- Colorectal Cancer Treatments and Studies 6
-
- Chemotherapy-induced cardiotoxicity and mitigation 6
-
- Sarcoma Diagnosis and Treatment 3
-
- Endometrial and Cervical Cancer Treatments 3
-
- Neuroendocrine Tumor Research Advances 4
-
- Chemotherapy-induced organ toxicity mitigation 3
Bruna Angelelli
27 papers receiving 585 citations
Peers
Comparison fields: 5 of 75
- Hepatology 205
- Oncology 313
- Cardiology and Cardiovascular Medicine 103
- Pulmonary and Respiratory Medicine 145
- Obstetrics and Gynecology 31
Countries citing papers authored by Bruna Angelelli
This map shows the geographic impact of Bruna Angelelli's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Bruna Angelelli with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Bruna Angelelli more than expected).
Fields of papers citing papers by Bruna Angelelli
This network shows the impact of papers produced by Bruna Angelelli. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Bruna Angelelli. The network helps show where Bruna Angelelli may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Bruna Angelelli, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2016 | 1 | |
| 2 | 2015 | 14 | |
| 3 | 2011 | 43 | |
| 4 | 2010 | 165 | |
| 5 | 2010 | 7 | |
| 6 | 2001 | 28 | |
| 7 | 2001 | 18 | |
| 8 | 2001 | 37 | |
| 9 | Pilot study on induction chemotherapy with cisplatin, epirubicin, etoposide and bleomycin in cervical cancer stage Ib, IIa and IIb. | 1999 | 1 |
| 10 | Comparative crossover trial of two intravenous doses of granisetron (1 mg vs 3 mg) + dexamethasone in the prevention of acute cis-platinum-induced emesis. | 1998 | 8 |
| 11 | Chemotherapy of advanced ovarian cancer. | 1997 | 1 |
| 12 | 1996 | 17 | |
| 13 | 1993 | 10 | |
| 14 | 1988 | 91 | |
| 15 | 1986 | 10 | |
| 16 | 1986 | 23 | |
| 17 | Epirubicin plasma and blood pharmacokinetics after single i.v. bolus in advanced cancer patients. | 1985 | 22 |
| 18 | Epirubicin pharmacokinetics after intrahepatic arterial and intraperitoneal administration. | 1985 | 12 |
| 19 | A new six-drug antiblastic regimen (R 14) at low doses (micropolychemotherapy) compared to CMF in the treatment of metastatic breast cancer: phase III study. | 1984 | 5 |
| 20 | 1983 | 17 |
About Bruna Angelelli
Bruna Angelelli is a scholar working on Hepatology, Oncology and Obstetrics and Gynecology, having authored 27 papers that have together received 609 indexed citations. Recurring topics across this work include Cancer Treatment and Pharmacology (9 papers), Colorectal Cancer Treatments and Studies (6 papers), Chemotherapy-induced cardiotoxicity and mitigation (6 papers), Hepatocellular Carcinoma Treatment and Prognosis (5 papers), Neuroendocrine Tumor Research Advances (4 papers), Chemotherapy-induced organ toxicity mitigation (3 papers), Endometrial and Cervical Cancer Treatments (3 papers) and Sarcoma Diagnosis and Treatment (3 papers). The work is most often cited by research in Hepatology (205 citations), Oncology (313 citations) and Cardiology and Cardiovascular Medicine (103 citations). Bruna Angelelli has collaborated with scholars based in Italy, Slovenia and Finland. Frequent co-authors include F Pannuti, Elena Strocchi, C. M. Camaggi, Andrea Martoni, Rita Golfieri, Emanuela Giampalma, Carlo Maurizio Camaggi, Maurizio Cosimelli, C.L. Maini and Secondo Lastoria. Their work appears in journals such as British Journal of Cancer, Annals of Oncology and European Journal of Cancer.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.